Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8:12:1611772.
doi: 10.3389/fcvm.2025.1611772. eCollection 2025.

Prognostic value of the ratio between right ventricular free wall longitudinal strain and systolic pulmonary artery pressure in patients with heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation

Affiliations

Prognostic value of the ratio between right ventricular free wall longitudinal strain and systolic pulmonary artery pressure in patients with heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation

Călin-Dinu Hădăreanu et al. Front Cardiovasc Med. .

Abstract

Background: In heart failure (HF) with reduced ejection fraction (HFrEF), ventricular secondary mitral regurgitation (V-sMR) leads to progressive impairment of right ventricular (RV) function and adversely affects outcomes. Non-invasive indices of RV-pulmonary artery (RVPA) coupling may offer enhanced prognostic value.

Methods: We retrospectively evaluated advanced echocardiographic surrogates of RVPA coupling in 104 HFrEF patients with V-sMR.

Results: Over a median follow-up of 526 days, 48 patients (46.2%) reached the composite endpoint of rehospitalization for HF decompensation or all-cause mortality. Patients who experienced events had significantly larger RV volumes, lower RV functional indices, and higher systolic pulmonary artery pressure (sPAP) compared with those without events. Among the RVPA coupling measures, the ratio of RV free-wall longitudinal strain (RVFWLS) to sPAP had the highest predictive accuracy (area under the curve 0.730), with an optimal cut-off of 0.46%/mmHg (71% sensitivity, 69% specificity). Kaplan-Meier analysis showed significantly lower event-free survival for patients with RVFWLS/sPAP < 0.46%/mmHg (log-rank p = 0.001). In multivariable Cox regression analysis, RVFWLS/sPAP (hazard ratio 0.110, 95% confidence interval 0.012-0.992; p = 0.049) emerged as an independent predictor of adverse outcomes.

Conclusion: The RVFWLS/sPAP ratio, with a cut-off value of 0.46%/mmHg, is a robust, independent prognostic marker in HFrEF patients with V-sMR.

Keywords: heart failure with reduced ejection fraction; prognosis; right ventricular strain to pulmonary artery pressure; right ventricular to pulmonary artery coupling; speckle-tracking echocardiography; three-dimensional echocardiography; ventricular secondary mitral regurgitation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart describing patients’ selection process.
Figure 2
Figure 2
Receiver operating characteristic curve for comparison of the prognostic value between echocardiographic right ventricular to pulmonary artery coupling indices. AUC, area under the curve; CI, confidence interval; RVEF, right ventricular ejection fraction; RVFAC, right ventricular fractional area change; RVFWLS, right ventricular free wall longitudinal strain; RVSV/ESV, right ventricular stroke volume to end-systolic volume; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annulus plane systolic excursion.
Figure 3
Figure 3
Kaplan–Meier event-free survival curves stratified by RVFWLS/sPAP < and ≥ 0.46%/mmHg. RVFWLS, right ventricular free wall longitudinal strain; sPAP, systolic pulmonary artery pressure.

References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42(36):3599–726. 10.1093/eurheartj/ehab368 - DOI - PubMed
    1. Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausmüller S, et al. Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ. (2021) 373:n1421. 10.1136/bmj.n1421 - DOI - PMC - PubMed
    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. (2022) 43(7):561–632. 10.1093/eurheartj/ehab395 - DOI - PubMed
    1. O’Gara PT, Mack MJ. Secondary mitral regurgitation. N Engl J Med. (2020) 383(15):1458–67. 10.1056/NEJMcp1903331 - DOI - PubMed
    1. Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R, et al. Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging. (2022) 23(5):E171–232. 10.1093/ehjci/jeab253 - DOI - PubMed

LinkOut - more resources